The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies
Open accessAbstract
Although components of possible Parkinson's disease can be found in very early documents, the first clear medical description was written in 1817 by James Parkinson.In the mid-1800s, Jean-Martin Charcot was particularly influential in refining and expanding this early description and in disseminating information internationally about Parkinson's disease.He separated Parkinson's disease from multiple sclerosis and other disorders characterized by tremor, and he recognized cases that later would likely be classified among the Parkinsonism-plus syndromes.Early treatments of Parkinson's disease were based on empirical observation, and anticholinergic drugs were used as early as the nineteenth century.The discovery of dopaminergic deficits in Parkinson's disease and the synthetic pathway of dopamine led to the first human trials of levodopa.Further historically important anatomical, biochemical, and physiological studies identified additional pharmacological and neurosurgical targets for Parkinson's disease and allow modern clinicians to offer an array of therapies aimed at improving function in this still incurable disease. I mportant historical anchors for the study ofParkinson's disease concern the early descriptions of the disorder, its separation from other neurological conditions, and the evolution of therapy from empirical observations to rational treatment designs based on the growing knowledge of anatomy, biochemistry, and physiology of the basal ganglia.Whereas the rest of this collection will focus on the contemporary and future directions of these issues, this article provides the background history of Parkinson's disease, highlighting persons and discoveries primarily from the nineteenth and early twentieth centuries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
de la Fuente-Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. (2001) · Science · doi:10.1126/science.1060937 · Cited by 991
Handbook of clinical neuropsychology
Filskov, S. B., & Boll, T. J. (1981) · Wiley eBooks · Cited by 868
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“A Phase III clinical trial is also undergoing for exenatide, an analogue of GDP-1, as a potential disease-modifying treatment for PD.575 Clinical trials of other drugs including AKST4290, BIIB094, DNL151, DNL201, NE3107 and sargramostim targeting to different immune modulatory pathways have also made some progress (cl…”
BackgroundInfluentialSignificance of long chain polyunsaturated fatty acids in human health
Zárate, R., el Jaber‐Vazdekis, N., Tejera, N., Pérez, J. A., & Rodríguez, C. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0153-6 · Cited by 551
Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management
Massano, J., & Bhatia, K. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008870 · Cited by 422
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
The two-century journey of Parkinson disease research
Przedborski, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 345
The role of histone modifications: from neurodevelopment to neurodiseases
Park, J., Lee, K., Kim, K., & Yi, S.-J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01078-9 · Cited by 297
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Loh, H. W., Ooi, C. P., Palmer, E., Barua, P. D., Dogan, S., Tuncer, T., Baygin, M., & Acharya, U. R. (2021) · Electronics · doi:10.3390/electronics10141740 · Cited by 144
“Parkinson’s was defined in the early 1800s, and further refined in the late 1800s by Jean-Martin Charcot, as a neurological syndrome characterized by slowness of movement (bradykinesia), involuntary tremors, rigidity, and postural instability [1,2].”
BackgroundPan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
Sigcha, L., Costa, N., Pavón, I., Costa, S., Arezes, P., López, J. M., & De Arcas, G. (2020) · Sensors · doi:10.3390/s20071895 · Cited by 126
Derk, J., MacLean, M., Juranek, J., & Schmidt, A. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000421 · Cited by 96
miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease
Mushtaq, G., H. Greig, N., Anwar, F., A. Zamzami, M., Choudhry, H., M. Shaik, M., A. Tamargo, I., & A. Kamal, M. (2016) · Medicinal Chemistry · doi:10.2174/1573406411666151030112140 · Cited by 78
Ashfaque Mostafa, T., Soltaninejad, S., McIsaac, T. L., & Cheng, I. (2021) · Sensors · doi:10.3390/s21196446 · Cited by 32
Metadata
- Authors
- Goetz, C. G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-09-01
- Volume
- 1
- Issue
- 1
- Pages
- a008862-a008862
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2155875767
- Cited by
- 470
- References
- 38
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.